Impact of human serum albumin in acute large-core ischemic stroke: an exploratory randomized controlled trial
- 1Department of Neurointervention, Zhangzhou Affiliated Hospital of Fujian Medical University
- 2Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University
- 3Department of Neurointervention, Fujian Medical University Union Hospital
Abstract
Background: Anterior-circulation large-vessel occlusion with a large ischemic core remains associated with substantial disability despite successful endovascular therapy (EVT). Human serum albumin (HSA) has shown neuroprotective effects in preclinical models, but its clinical benefit after successful reperfusion is uncertain.
Methods: We conducted a single-center, prospective, open-label, endpoint-blinded exploratory randomized controlled trial in 60 adults with anterior-circulation large-core acute ischemic stroke due to large-vessel occlusion. Participants were randomized 1:1 before EVT. After angiographic confirmation of successful reperfusion (eTICI 2b-3), the albumin group received 100 mL of 20% HSA intravenously and the control group received 100 mL of normal saline with matched timing. The primary outcome was 90-day functional independence (modified Rankin Scale score 0–2). Net water uptake (NWU) was an exploratory imaging biomarker; symptomatic intracranial hemorrhage (sICH) and 90-day mortality were safety outcomes.
Results: All 60 randomized participants achieved successful reperfusion, received the allocated intervention, and were included in the intention-to-treat analysis. In the albumin and control groups, respectively, 21/30 (70.0%) and 20/30 (66.7%) participants were male; mean ± SD age was 68.0 ± 9.3 and 66.3 ± 10.7 years, admission National Institutes of Health Stroke Scale (NIHSS) score was 16.3 ± 4.8 and 16.4 ± 7.1, and admission Alberta Stroke Program Early CT Score (ASPECTS) on noncontrast CT (NCCT) was 5.0 ± 1.5 and 4.9 ± 1.3. Functional independence occurred in 11/30 participants (36.7%) in each group (risk ratio, 1.00 [95% CI, 0.51–1.94]; risk difference, 0.0 percentage points [95% CI, −24.4 to 24.4]; odds ratio, 1.00 [95% CI, 0.35–2.86]; Fisher exact p = 1.000). The NWU treatment-by-time interaction was not statistically significant (Wald chi-square = 3.40, 2 df; p = 0.182). sICH occurred in 2/30 participants (6.7%) in each group, and 90-day mortality occurred in 2/30 (6.7%) versus 4/30 (13.3%).
Conclusion: In this small exploratory randomized trial, immediate post-reperfusion 20% HSA did not demonstrate a statistically significant improvement in 90-day functional independence or NWU. Wide confidence intervals do not exclude clinically meaningful benefit or harm; larger adequately powered multicenter trials are needed.
Clinical trial registration: https://clinicaltrials.gov/study/NCT06629116 ; Unique Identifier: NCT06629116.
Related
- Remote Ischemic Conditioning Modulates Spinal Reflex Excitability in Healthy Young Adults: A Pilot Randomized Controlled Trial
- mHealth-based lifestyle intervention for hypertension in community-dwelling adults: a cluster-randomized controlled trial with exploratory multi-omics analyses
- Effects of Probiotic Supplementation on Performance Retention During Detraining and Recovery After Simulated Return-to-Training Stress in College Volleyball Players: An Exploratory Randomized, Single-Blind, Placebo-Controlled Trial
- Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial
- Effect of delayed remote ischemic preconditioning on major cardiovascular and cerebrovascular events in major vascular surgery: the protocol of DRIPC randomized controlled trial
BibTeX
@article{liu2026impact,
title = {{Impact of human serum albumin in acute large-core ischemic stroke: an exploratory randomized controlled trial}},
author = {Shuyi Liu and Zhi-Nan Pan and Ding-Lai Lin and Xiao-Hui Lin and Lisan Zeng and Yan-Min Wu and Mei-Hua Wu and Weifeng Huang and Cai-Xia Li and Yi-Ning Yang and Jin-Hua Ye and Ying Wu and Huanghuang Chen and Tingyu Yi and Wen-Huo Chen},
journal = {Frontiers in Neurology},
year = {2026},
month = nov,
doi = {10.3389/fneur.2026.1947414},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1947414/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Impact of human serum albumin in acute large-core ischemic stroke: an exploratory randomized controlled trial
AU - Shuyi Liu
AU - Zhi-Nan Pan
AU - Ding-Lai Lin
AU - Xiao-Hui Lin
AU - Lisan Zeng
AU - Yan-Min Wu
AU - Mei-Hua Wu
AU - Weifeng Huang
AU - Cai-Xia Li
AU - Yi-Ning Yang
AU - Jin-Hua Ye
AU - Ying Wu
AU - Huanghuang Chen
AU - Tingyu Yi
AU - Wen-Huo Chen
PY - 2026
DA - 2026/11/03
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1947414
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1947414/full
AB - Background: Anterior-circulation large-vessel occlusion with a large ischemic core remains associated with substantial disability despite successful endovascular therapy (EVT). Human serum albumin (HSA) has shown neuroprotective effects in preclinical models, but its clinical benefit after successful reperfusion is uncertain. Methods: We conducted a single-center, prospective, open-label, endpoint-blinded exploratory randomized controlled trial in 60 adults with anterior-circulation large-core acute ischemic stroke due to large-vessel occlusion. Participants were randomized 1:1 before EVT. After angiographic confirmation of successful reperfusion (eTICI 2b-3), the albumin group received 100 mL of 20% HSA intravenously and the control group received 100 mL of normal saline with matched timing. The primary outcome was 90-day functional independence (modified Rankin Scale score 0–2). Net water uptake (NWU) was an exploratory imaging biomarker; symptomatic intracranial hemorrhage (sICH) and 90-day mortality were safety outcomes. Results: All 60 randomized participants achieved successful reperfusion, received the allocated intervention, and were included in the intention-to-treat analysis. In the albumin and control groups, respectively, 21/30 (70.0%) and 20/30 (66.7%) participants were male; mean ± SD age was 68.0 ± 9.3 and 66.3 ± 10.7 years, admission National Institutes of Health Stroke Scale (NIHSS) score was 16.3 ± 4.8 and 16.4 ± 7.1, and admission Alberta Stroke Program Early CT Score (ASPECTS) on noncontrast CT (NCCT) was 5.0 ± 1.5 and 4.9 ± 1.3. Functional independence occurred in 11/30 participants (36.7%) in each group (risk ratio, 1.00 [95% CI, 0.51–1.94]; risk difference, 0.0 percentage points [95% CI, −24.4 to 24.4]; odds ratio, 1.00 [95% CI, 0.35–2.86]; Fisher exact p = 1.000). The NWU treatment-by-time interaction was not statistically significant (Wald chi-square = 3.40, 2 df; p = 0.182). sICH occurred in 2/30 participants (6.7%) in each group, and 90-day mortality occurred in 2/30 (6.7%) versus 4/30 (13.3%). Conclusion: In this small exploratory randomized trial, immediate post-reperfusion 20% HSA did not demonstrate a statistically significant improvement in 90-day functional independence or NWU. Wide confidence intervals do not exclude clinically meaningful benefit or harm; larger adequately powered multicenter trials are needed. Clinical trial registration: https://clinicaltrials.gov/study/NCT06629116 ; Unique Identifier: NCT06629116.
SN - 1664-2295
ER -